Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 May 2015 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise and Projection of Improved Cash Position at the End of 2015 | 20 May 2015 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 20 May 2015 |
| Genmab Enters Commercial DuoBody® Technology Agreement with BioNTech in Field of Immuno-oncology | 19 May 2015 |
| HuMax-TF-ADC and Daratumumab Data to Be Presented at 2015 ASCO Annual Meeting | 13 May 2015 |